Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

International Partnership for Microbicides (IPM)

Status and phase: Completed; Phase 1

Conditions: Human Immunodeficiency Virus

Treatments: Combination Product: Placebo Vaginal Ring; Device: Condom

Study type: Interventional

Funder types: Industry

Identifiers

NCT01755741

IPM 029

Details and patient eligibility

About

This trial will assess the potential impact of a vaginal ring on condom use by comparing the performance (total clinical failure, clinical slippage, and clinical breakage) of a standard male lubricated latex condom when the female partner is wearing the vaginal ring and when the female partner is not wearing the vaginal ring.

Enrollment: 70 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Mutually monogamous heterosexual couples; current relationship ≥3 months; and who can give written informed consent;
2. Age ≥18 to ≤45 years (females) or ≥18 to ≤55 years (males) at time of the screening visit;
3. Healthy on the basis of medical history;
4. Not at risk of pregnancy, i.e., female is surgically sterile, using an IUD, or using effective hormonal contraception, or has a vasectomized partner. The use of vaginal contraceptive rings will not be allowed;
5. Sexually active and agree to have at least 8 acts of penile-vaginal intercourse using a study condom over 2 periods of up to 4 weeks each;
6. Agree to use only the condoms provided by trial personnel during the time of participation. Additional lubricant will be provided; use of non-study lubricants will not be allowed;
7. Agree to not use other vaginal products, except menstrual absorption products (e.g. tampons) and study lubricant during the trial;
8. Available for all visits and consent to follow all procedures scheduled for the trial;
9. At low risk for HIV infection.

Exclusion criteria

1. Males with untreated erectile dysfunction;
2. Female with positive pregnancy test;
3. Either partner allergic to natural latex or vaginal lubricants such as Astroglide ®;
4. History by self-report of recurrent or a recently-treated (within past 2 weeks) sexually transmitted infection (e.g. gonorrhea, syphilis, chlamydia) or HIV(+);
5. Currently using condoms for protection against sexually transmitted infection;
6. Either partner taking any topical or oral medication to treat a urogenital condition at enrollment, except medication for the male partner to treat erectile dysfunction (e.g., tadalafil, sildenafil);
7. Either partner with a self-reported or clinically diagnosed urogenital condition (e.g. itching, burning, irritation, etc.) that, in the opinion of the Investigator, could affect use of the study condoms or ability to interpret trial data;
8. Females, based on findings from a pelvic examination, who are not suitable candidates for wearing the vaginal ring (anatomical condition, current vaginal infection, etc.);
9. Current participation in a study or other research involving a drug, device or other product;
10. Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

70 participants in 2 patient groups

Placebo Vaginal Ring

Experimental group

Description:

Placebo vaginal ring with condom use

Treatment:

Device: Condom

Combination Product: Placebo Vaginal Ring

Condom

Other group

Description:

Male condoms during vaginal intercourse in presence and absence of the vaginal ring.

Treatment:

Device: Condom